Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
Purpose: To describe the results of the off-label use of eltrombopag in patients with solid tumors and thrombocytopenia that limits chemotherapy. Methods: Retrospective observational study including all patients with solid tumors who were treated with eltrombopag for thrombocytopenia during the...
Saved in:
| Main Authors: | María Henar García Lagunar, Pablo Cerezuela Fuentes, Mónica Martínez Penella, Dolores Paula Gutiérrez-Meca Maestre, María García Coronel, María José Martínez Ortiz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-02-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/8580.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01) -
The establishment of an expected concentration reference range for eltrombopag in the individualized treatment of pediatric immune thrombocytopenia
by: Nan Wang, et al.
Published: (2025-08-01) -
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01) -
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01) -
Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context
by: Yunfei Chen, et al.
Published: (2025-09-01)